Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Ingrid Delaet Biography and Net Worth

Insider of Neurocrine Biosciences

Ingrid Delaet, Ph.D., was appointed Vice President, Regulatory Affairs in 2021, and Chief Regulatory Officer in October 2022. She is responsible for leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has more than 25 years of drug development experience in several therapeutic areas, including immunology, hepatology, cardiovascular, and metabolic diseases. Prior to joining Neurocrine Biosciences, she served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016. Between 1997 and 2016, Dr. Delaet held various positions of increasing responsibility at Bristol-Myers Squibb in the United States, first in Clinical Research and Development and then in Global Regulatory Affairs, where she served as Therapeutic Area Lead for Immunology. Prior to Bristol-Myers Squibb, she held positions in clinical research at CellPro, Inc. and Wyeth-Ayerst Research. She received her Ph.D. in Immunology and her M.Sc. in Pharmaceutical Sciences from The Free University of Brussels, Belgium.

What is Ingrid Delaet's net worth?: The estimated net worth of Ingrid Delaet is at least $339,497.94 as of December 17th, 2024. Dr. Delaet owns 2,507 shares of Neurocrine Biosciences stock worth more than $339,498 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Delaet may own. Learn More about Ingrid Delaet's net worth.
How do I contact Ingrid Delaet?: The corporate mailing address for Dr. Delaet and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Ingrid Delaet's contact information.
Has Ingrid Delaet been buying or selling shares of Neurocrine Biosciences?: During the last quarter, Ingrid Delaet has sold $147,285.00 in Neurocrine Biosciences stock. Most recently, Ingrid Delaet sold 1,091 shares of the business's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a transaction totalling $147,285.00. Following the completion of the sale, the insider now directly owns 2,507 shares of the company's stock, valued at $338,445. Learn More on Ingrid Delaet's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 44 times. They sold a total of 542,972 shares worth more than $74,251,850.99. The most recent insider tranaction occured on December, 17th when insider Ingrid Delaet sold 1,091 shares worth more than $147,285.00. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 12/17/2024.

Ingrid Delaet Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/17/2024	Sell	1,091	$135.00	$147,285.00	2,507
8/13/2024	Sell	7,143	$150.10	$1,072,164.30	2,507
8/6/2024	Sell	273	$147.70	$40,322.10	6,607
5/6/2024	Sell	273	$140.55	$38,370.15	7,507
3/21/2024	Sell	5,000	$145.06	$725,300.00	7,507
3/11/2024	Sell	200	$140.00	$28,000.00	7,507
3/8/2024	Sell	1,800	$140.03	$252,054.00	7,507
2/29/2024	Sell	273	$135.51	$36,994.23	7,507
8/28/2023	Sell	1,431	$107.52	$153,861.12	5,931

Ingrid Delaet Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $135.42

$134.12

$137.01

50 Day Range

MA: $123.99

$115.08

$136.69

2 Week Range

Now: $135.42

$110.95

$157.98

Volume

2,265,589 shs

Average Volume

884,102 shs

Market Capitalization

$13.71 billion

P/E Ratio

36.31

Dividend Yield

N/A

Beta

0.34